Allimax Nutraceuticals US Completes Lyme Disease Clinical Trial

Allimax Nutraceuticals US, in conjunction with the Health Healing and Hope Foundation, has completed a Lyme disease clinical study being conducted in Texas by Dr.’s Joan Vandergriff ND and Hamid Moayad DO. The study was sponsored by Allimax Nutraceuticals US and Allicin International L.T.D. The purpose of the study was intended to show eradication of the blood borne Borrelia Spirochete and the cystic form of the same (which cause Lyme disease) by treatment with Allisure® AC-23 stabilized allicin extract.

The Lyme disease study was completed December 31, 2006 but has not yet been published. According to the company, results indicate that after using Allisure® AC-23 stabilized allicin for 3 months, both in capsule and liquid forms, there was a significant eradication or reversal of the cystic form of spirochetes and Borrelia Burgdorferi. The study will be published later this year, and currently, the company is completing screening of participants by dark field microscopy and will be sending their blood to Igenex labs for testing as well.

James R. Walton, President
Allimax Nutraceuticals US
[email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.